Is MannKind Corp. overvalued or undervalued?

As of 9 November 2016, MannKind Corp. moved from does not qualify to risky. The company is currently overvalued based on its valuation metrics. Key ratios include a P/E ratio of 26, an EV to EBITDA of 13.61, and a PEG ratio of 0.06, which suggests a significant discrepancy in growth expectations relative to its price.
In comparison to peers, MannKind Corp. has a P/E ratio of 38.35, which is notably higher than Catalyst Pharmaceuticals, Inc. at 12.14, indicating that MannKind may be overvalued despite its risky classification. Additionally, while MannKind's 5-year return of 169.71% outperformed the S&P 500's 96.61%, its year-to-date return of -12.75% underperformed against the S&P 500's 12.22%, reinforcing the notion of overvaluation in the current market context.